Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancerKen Uchibori, Ryohei Katayama|Nature Communications|2017Cited by 409
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung CancerRyohei Katayama, Naoya Fujita|EBioMedicine|2015Cited by 140
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistanceKoutaroh Okada, Ryohei Katayama|EBioMedicine|2019Cited by 125
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancerHayato Mizuta, Ryohei Katayama|Nature Communications|2021Cited by 100
Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylationRay Sagawa, Ryohei Katayama|JCI Insight|2021Cited by 47